ReviewDrug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy2016
The rapid spread of carbapenem-resistant Enterobacteriaceae.
Review in Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07167173 (Predictive Model for Multidrug Resistance in Patients Admitted to the Emergency Department With Sepsis), which is not on this map. Cited by 210 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Predictive Model for Multidrug Resistance in Patients Admitted to the Emergency Department With Sepsis
Who cites it
210 citing papers in PubMed, 4 syntheses or guidelines pooled it, 407 citations in OpenAlex.
- Global trends in carbapenem-resistant gram-negative bacteria research (2020-2025): a bibliometric analysis and systematic review.Frontiers in cellular and infection microbiology · 2025Pooled it
- A systematic review of efficacy and safety of newer drugs approved from 2016 to 2023 for the treatment of complicated urinary tract infections.Annals of medicine · 2024Pooled it
- Systematic Review and Meta-Analysis of Clinical Efficacy and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections.International journal of molecular sciences · 2024Pooled it
- Efficacy and Safety of Ceftazidime-Avibactam for the Treatment of Carbapenem-ResistantMicrobiology spectrum · 2022Pooled it
- Trial
- Safety, Pharmacokinetics, and Food Effect of Tebipenem Pivoxil Hydrobromide after Single and Multiple Ascending Oral Doses in Healthy Adult Subjects.Antimicrobial agents and chemotherapy · 2019Trial
- Safety, Tolerability, Pharmacokinetics, and Drug Interaction Potential of SPR741, an Intravenous Potentiator, after Single and Multiple Ascending Doses and When Combined with β-Lactam Antibiotics in Healthy Subjects.Antimicrobial agents and chemotherapy · 2019Trial
- Post-infection colonization and recurrent infections by ST11-KL64 carbapenem-resistantVirulence · 2026Article
- Characterization of defensome genes and mobile genetic Elements in different types of pasture soil agroecosystems from the Brazilian Amazon.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Carbapenem-Resistant Enterobacterales (CRE) in Europe: Surveillance Challenges, Emerging Threats and Public Health Preparedness.Antibiotics (Basel, Switzerland) · 2026Review
- Budget impact analysis of aztreonam-avibactam for metallo-β-lactamase carbapenem-resistant enterobacterales infections in China.Infection · 2026Article
- In vitro activity of aztreonam/avibactam and comparators against Enterobacterales isolates from patients with hospital-acquired pneumonia, ventilator-associated pneumonia, and complicated intra-abdominal infections (ATLAS, 2021-2022).The Journal of antimicrobial chemotherapy · 2026Article
- A nomogram for assessing secondary infection risk in hospitalized patients with intestinal CRE colonization: a prospective cohort study.Annals of clinical microbiology and antimicrobials · 2026Article
- High prevalence of blaBMC microbiology · 2026Article
- Clinically Significant Carbapenemases in Gram-Negative Pathogens: Molecular Diversity and Advances in β-Lactamase Inhibitor Therapy.Antibiotics (Basel, Switzerland) · 2026Review
- Within-host co-evolution of KPC variants: plasmid-mediated dissemination ofMicrobiology spectrum · 2026Article
- Mapping 25 years of research on gut microbiota and antibiotic resistance: bibliometric insights and future directions.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- First report of anMicrobiology spectrum · 2026Article
- Predictive Factors for Upper Urinary Tract Stones Combined with Carbapenem-Resistant Enterobacteriaceae Associated Urinary Tract Infections.Infection and drug resistance · 2026Article
- Hidden Toll of CRE Colonization: Tripled Three-Year Mortality Risk and Increased Bloodstream Infection Burden After Allo-HSCT-A Propensity-Adjusted Study.Infection and drug resistance · 2026Article
150 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Carbapenems, our one-time silver bullet for multidrug resistant bacterial infections, are now threatened by widespread dissemination of carbapenem-resistant Enterobacteriaceae (CRE). Successful expansion of Enterobacteriaceae clonal groups and frequent horizontal gene transfer of carbapenemase expressing plasmids are causing increasing carbapenem resistance. Recent advances in genetic and phenotypic detection facilitate global surveillance of CRE diversity and prevalence. In particular, whole genome sequencing enabled efficient tracking, annotation, and study of genetic elements colocalized with carbapenemase genes on chromosomes and on plasmids. Improved characterization helps detail the co-occurrence of other antibiotic resistance genes in CRE isolates and helps identify pan-drug resistance mechanisms. The novel β-lactamase inhibitor, avibactam, combined with ceftazidime or aztreonam, is a promising CRE treatment compared to current colistin or tigecycline regimens. To halt increasing CRE-associated morbidity and mortality, we must continue quality, cooperative monitoring and urgently investigate novel treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.